Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial.
Michielsens, Celia A J
Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial. [electronic resource] - Trials Jan 2020 - 90 p. digital
Publication Type: Journal Article; Randomized Controlled Trial
1745-6215
10.1186/s13063-019-4000-5 doi
Adalimumab--adverse effects
Adolescent
Adult
Antibodies, Monoclonal--adverse effects
Arthritis, Psoriatic--drug therapy
Bayes Theorem
Case-Control Studies
Cost-Benefit Analysis
Dose-Response Relationship, Drug
Etanercept--adverse effects
Follow-Up Studies
Humans
Infliximab--adverse effects
Netherlands--epidemiology
Quality of Life
Research Design
Severity of Illness Index
Spondylarthritis--drug therapy
Tumor Necrosis Factor Inhibitors--adverse effects
Young Adult
Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial. [electronic resource] - Trials Jan 2020 - 90 p. digital
Publication Type: Journal Article; Randomized Controlled Trial
1745-6215
10.1186/s13063-019-4000-5 doi
Adalimumab--adverse effects
Adolescent
Adult
Antibodies, Monoclonal--adverse effects
Arthritis, Psoriatic--drug therapy
Bayes Theorem
Case-Control Studies
Cost-Benefit Analysis
Dose-Response Relationship, Drug
Etanercept--adverse effects
Follow-Up Studies
Humans
Infliximab--adverse effects
Netherlands--epidemiology
Quality of Life
Research Design
Severity of Illness Index
Spondylarthritis--drug therapy
Tumor Necrosis Factor Inhibitors--adverse effects
Young Adult